Final Report - TRIDENT (Therapeutic molecules for treatment of solid tumours by modulating death receptor-mediated apoptosis)
Project ID: 37686Funded under: FP6-LIFESCIHEALTH
This is the final report for the TRIDENT project which aimed to define and develop novel therapeutic strategies and tumour-selective agents to treat solid tumours. As outlined in the report, a number of patents were filed protecting the intellectual content generated in this program and the production protocols for generating purified TRAIL variants suitable for preclinical and early clinical studies were completed. Pharmacokinetic and biodistribution properties of the patented lead molecules and pre-clinical animal studies were also conducted and are currently ongoing. These can now be used by a start-up small and medium-sized enterprise (SME) to exploit and commercialise the knowledge generated over the course of this project.
Download application/msword (379392)
Record Number: 12233 / Last updated on: 2011-04-14